4 trials
| Products | Diagnoses | Sponsor | ||||
|---|---|---|---|---|---|---|
CLARITY AD NCT03887455 CLARITY AD tested lecanemab in early Alzheimer’s disease. It is the main efficacy trial behind the US traditional approval. | Lecanemab | Alzheimer’s disease | Eisai | 2023 | ||
TRAILBLAZER-ALZ 2 NCT04437511 TRAILBLAZER-ALZ 2 tested donanemab in early Alzheimer’s disease and is the main efficacy trial behind the US approval. | Donanemab | Alzheimer’s disease | Eli Lilly | 2023 | ||
ENGAGE NCT02477800 ENGAGE was a phase 3 aducanumab trial that did not meet its primary endpoint as designed. It is here as a failure, not as support for using the drug. | Aducanumab | Alzheimer’s disease | Biogen | 2019 | ||
EXPEDITION 3 NCT01900665 EXPEDITION 3 tested solanezumab in mild Alzheimer’s disease and did not meet its primary endpoint. It is included as a negative amyloid-antibody result. | none | Alzheimer’s disease | Eli Lilly | 2016 |